BioPharma Resources

Drug Trial Radar · NCT03199989

Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)

Last checked: Nov 19, 2026Latest source record: Mar 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,254 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,254

Planned (sponsor's estimate)

Start

Jun 1, 2017

Primary completion

Jul 31, 2021

Study completion Jul 31, 2024

Sponsor

Lead sponsor
Peking University Cancer Hospital & InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peking Union Medical College Hospital; Peking University People's Hospital
First posted
Jun 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to design a prospective randomized clinical trial to explore whether postoperative adjuvant chemotherapy may provide survival benefit for stage II colon cancer patients with high risk factors.Therefore the investigators can provide high level clinical evidence of indications for patients with colon cancer with stage II colon cancer.

Conditions

  • Adjuvant Chemotherapy

Interventions

  • CapeOX(Capecitabine+Oxaliplatin)Drug

    Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX(Capecitabine+Oxaliplatin)for 6 months

  • ObservationOther

    Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-year disease free survivalTime frame: At least 3 years after the last patient enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing cancer hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.